{"id":"kad-1229","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":{"chemblId":"CHEMBL6045616","moleculeType":null,"molecularWeight":"467.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KAD-1229 activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of the vessel wall. This results in vasodilation and a reduction in peripheral vascular resistance, thereby lowering blood pressure. The drug is designed for oral administration in the treatment of hypertension.","oneSentence":"KAD-1229 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:43.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07444424","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-13","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT04349696","phase":"PHASE4","title":"Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)","status":"COMPLETED","sponsor":"Orient Europharma Co., Ltd.","startDate":"2014-02-11","conditions":"Type 2 Diabetes Mellitus, Liver Dysfunction","enrollment":16},{"nctId":"NCT02154347","phase":"PHASE4","title":"Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Type 2 Diabetes Mellitus","enrollment":178},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT02143765","phase":"PHASE4","title":"Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Zhongda Hospital","startDate":"2014-05","conditions":"Type 2 Diabetes Mellitus","enrollment":248},{"nctId":"NCT02503943","phase":"PHASE4","title":"Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital of Third Military Medical University","startDate":"2015-05","conditions":"Type 2 Diabetes, Overweight, Obesity","enrollment":90},{"nctId":"NCT01333592","phase":"PHASE3","title":"Long-term Study of KAD-1229 in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Type 2 Diabetes","enrollment":136},{"nctId":"NCT01456130","phase":"PHASE3","title":"Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11","conditions":"Diabetes Mellitus","enrollment":67},{"nctId":"NCT00663884","phase":"PHASE4","title":"Glufast On Insulin Glargine Trial in Type 2 DM","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":167},{"nctId":"NCT01403818","phase":"PHASE1","title":"A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-06","conditions":"Healthy, Pharmacokinetics of ASP1941, Pharmacokinetics of Mitiglinide","enrollment":60},{"nctId":"NCT01443221","phase":"PHASE1","title":"Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2010-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT01422590","phase":"PHASE1","title":"Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-05","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01037842","phase":"PHASE3","title":"Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2006-08","conditions":"Type 2 Diabetes","enrollment":145},{"nctId":"NCT00519142","phase":"PHASE3","title":"Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Elixir Pharmaceuticals","startDate":"2007-08","conditions":"Diabetes Mellitus, Type 2","enrollment":367},{"nctId":"NCT00369148","phase":"PHASE4","title":"Combination of Glinides With Premixed Insulin","status":"COMPLETED","sponsor":"Keio University","startDate":"2004-07","conditions":"Type 2 Diabets Mellitus","enrollment":60},{"nctId":"NCT00566865","phase":"PHASE1","title":"Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil","status":"COMPLETED","sponsor":"Elixir Pharmaceuticals","startDate":"2007-11","conditions":"Type 2 Diabetes Mellitus","enrollment":14},{"nctId":"NCT00461617","phase":"PHASE3","title":"Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2006-08","conditions":"Diabetes","enrollment":291}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ADENOCARCINOMA"},{"count":1,"reaction":"BENIGN PROSTATIC HYPERPLASIA"},{"count":1,"reaction":"BLADDER CANCER"},{"count":1,"reaction":"CATARACT"},{"count":1,"reaction":"COLONIC STENOSIS"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DIABETIC RETINOPATHY"},{"count":1,"reaction":"LARGE INTESTINE CARCINOMA"},{"count":1,"reaction":"METASTASES TO LYMPH NODES"},{"count":1,"reaction":"VISUAL ACUITY REDUCED"}],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"KAD-1229","genericName":"KAD-1229","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KAD-1229 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}